Long-Term Outcome of VT Ablation in NIDCM
of Pennsylvania for radiofrequency CA between January 1999 and December 2014. All patients had evidence of left ventricular (LV) dilation and systolic impairment (LV ejection fraction [LVEF] <50%) persistent for at least 9 months, despite optimal medical treatment after the initial diagnosis. 12, 13 Patients with significant coronary artery disease (>50% stenosis, assessed by coronary angiography or coronary artery computed tomography), congenital heart disease, hypertrophic cardiomyopathy, arrhythmogenic right ventricular (RV) cardiomyopathy, LV noncompaction, restrictive cardiomyopathy, (sub)acute myocarditis, cardiac sarcoidosis, toxic cardiomyopathy, tachycardia-induced cardiomyopathy, or primary valvular abnormalities were excluded. All patients were treated according to the institutional guidelines of the University of Pennsylvania Health System and provided written informed consent.
Electrophysiological Study
All patients underwent the procedure in the fasting state. Ablation was performed under conscious sedation whenever possible. General anesthesia was used when necessary at the discretion of the operator or anesthesiologist for ventilation, oxygenation, or patient comfort and during epicardial mapping and ablation. AADs were routinely discontinued ≥5 half-lives before the procedure, with the exception of amiodarone, which was discontinued at least 3 days beforehand. Recurrent unstable arrhythmias necessitated continued AAD therapy in selected patients at the time of the procedure. Catheters were placed under fluoroscopic guidance. A standard transvenous 6F quadripolar catheter with 5-mm interelectrode distance (Bard Inc, Delran, NJ) was placed at the RV apex. An 8F 64-element phased-array intracardiac echocardiography catheter (AcuNav; Acuson, Mountain View, CA) was used routinely for cases after 2005 to assist catheter positioning, to assess tissue-catheter contact, and to monitor for complications. In 376 out of 442 (85%) procedures, a deflectable 3.5-mm open-irrigated tip catheter (NaviStar ThermoCool; Biosense Webster, Inc, Diamond Bar, CA) was used for mapping and ablation; a bidirectional closed-irrigated ablation catheter (Chilli; Boston Scientific, Natick, MA) was used in 36 (8%) procedures. In the remaining 30 (7%) procedures (all before 2002), a nonirrigated 4-mm tip ablation catheter (NaviStar; Biosense Webster, Inc) was used. The mapping/ ablation catheter was advanced to the RV (transvenous approach), LV (retrograde aortic or transseptal approach), or epicardial space according to the presumed site of origin of the VT or the underlying substrate. Programmed ventricular stimulation was delivered, with triple extrastimuli from at least 2 RV or LV sites with at least 2 drive cycle lengths (CLs). The 12-lead ECG morphology of all spontaneous VTs (when available) and the intracardiac near-field and far-field electrograms of the implantable cardioverter defibrillator (ICD) were collected and compared with the induced VT(s) during the procedure. Induced VT(s) were identified as clinical if they matched the CL and morphology of stored ICD electrograms (near-field and far-field) and the 12-lead ECG when available. Isoproterenol was used in select cases to facilitate induction of the clinical VT.
Endocardial Mapping
A high-density 3-dimensional electro-anatomic map (CARTO; Biosense Webster, Inc) was created during sinus or paced rhythm, maintaining a color and surface fill threshold of 15 mm to ensure adequate sampling and representation of the entire endocardial surface area to identify low voltage areas and abnormal electrograms consistent with scar. The bipolar signals were filtered at 30 to 400 Hz (CARTO V.9 and V.7 systems; Biosense Webster, Inc.) or 16 to 500 Hz (CARTO-3 system; Biosense Webster, Inc.) and were displayed at 100 mm/s speed. The peak-to-peak signal amplitude of the bipolar electrogram was measured automatically and confirmed during manual review. The electrogram signals were displayed as color gradients on a 3-dimensional computerized bipolar voltage map. Reference values for identifying abnormal endocardial bipolar and unipolar and epicardial bipolar electrogram signal amplitudes in the RV and LV were defined according to previously established criteria. [14] [15] [16] An endocardial bipolar signal amplitude >1.5 mV either in the RV or in the LV and an endocardial unipolar signal amplitude >8.3 mV in the LV and RV septum and >5.5 mV in the RV free wall were categorized as normal and represented in the electro-anatomic map by purple color. Abnormal voltage areas were represented by nonpurple range of colors, with the most abnormal signal amplitude (arbitrary defined as <0.5 mV) represented by red color. Particular attention was paid to define the valvular planes. Tricuspid and mitral valvular sites were identified by the fluoroscopic catheter tip positions at the ventricular base with discrete bipolar recordings that demonstrated both sharp atrial and ventricular signals of approximately equal amplitude and confirmed with the use of direct valve visualization with intracardiac echocardiography (for cases after 2005). The pulmonic valve was carefully identified by passing the mapping catheter into the pulmonary artery and slowly withdrawing it until an RV electrograms was identified, and RV capture was possible and confirmed with the use of direct visualization of the valve with intracardiac echocardiography (for cases after 2005). Valvular sites were given a location-only tag to preclude their influence on the voltage map color. Careful attention was paid to record multiple endocardial electrograms around valvular structures.
Epicardial Mapping
Epicardial mapping was performed when (1) the 12-lead ECG of the VT suggested an epicardial origin; (2) there was evidence of epicardial substrate on imaging studies (eg, magnetic resonance, intracardiac echocardiography); (3) there was unipolar electrogram abnormality (<8.3
WHAT IS KNOWN
• The management of recurrent ventricular tachycardia in the setting of nonischemic dilated cardiomyopathy is challenging due to the complexity of the underlying arrhythmogenic substrates, typically located at the basal perivalvular regions and at the interventricular septum and with a high prevalence of mid-myocardial and sub-epicardial substrates.
• Prior series with catheter ablation have reported worse arrhythmia-free survival following endocardial-only procedures, with a substantial improvement in short to mid-term VT-free survival when a combined endocardial-epicardial approach is adopted.
• Data on long-term outcomes following catheter ablation are insufficient, and the impact of catheter ablation on the long-term use of antiarrhythmic drug therapy and mortality is unknown.
WHAT THE STUDY ADDS
• Catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy is a safe and effective approach to achieve long-term arrhythmia control in most patients.
• Endocardial with adjuvant epicardial ablation (in case of persistent VT inducibility or clinical recurrence following endocardial-only procedure) provide good long-term arrhythmia-free survival. The majority of patients have complete ventricular tachycardia control, and most of the remaining patients have a substantial improvement in ventricular tachycardia burden with limited need for antiarrhythmic drugs.
• Recurrent VT is independently associated with increased risk of subsequent death/transplant. In these patients, a more aggressive treatment of recurrent VT may translate into a mortality benefit. mV) in the presence of no or minimal bipolar (<1.5 mV) electrogram abnormality; and (4) there was failure of endocardial ablation (either early VT recurrence or persistent inducibility of clinical VT). Access to the pericardial space was obtained using the percutaneous subxiphoid approach described by Sosa et al. 17 An 8F sheath (or deflectable sheath) was introduced into the pericardial space, and the mapping/ablation catheter was advanced through the sheath. Detailed voltage mapping was performed with a surface and color fill threshold maintained at 15 mm. The reference value for defining abnormal electrograms in the epicardium was <1.0 mV, as previously reported. 4 Dense scar was also arbitrarily defined as <0.5 mV for display purposes for the epicardial electroanatomic maps. To further limit the influence of epicardial fat and small-vessel coronary vasculature (ie, vessels that cannot be directly appreciated by coronary angiogram) on the low-voltage region, the contiguous low-voltage electrograms had to demonstrate not only low amplitude but also discrete late potentials (recorded after the QRS of the surface ECG) and demonstrate broad multicomponent or split signals. Signals >1.0 mV that also demonstrated abnormal, multicomponent, split or late potentials were also tagged and if adjacent to confluent areas of low voltage typically included in substrate-based ablation targets.
Catheter Ablation
The primary ablation end point was elimination of the clinical VT(s) and all mappable nonclinical VT(s). All induced VT(s) with a CL Figure 1 . Examples of typical distribution of endocardial ablation linear lesions across abnormal left ventricle to valve annulus in a patient with multiple unmappable ventricular tachycardias (VTs). Linear lesions transecting the putative VT isthmuses were placed through the sites of best pace maps with long stimulus to QRS and were anchored to the valve annulus. >250 ms were also considered potentially relevant and routinely targeted for ablation. For hemodynamically tolerated VT(s), entrainment mapping was performed at sites showing diastolic activity to identify critical sites of the VT re-entrant circuit. Sites with concealed QRS fusion and return cycle within 30 ms of the VT CL with matching stimulus-QRS and electrogram-QRS intervals or where VT terminated during pacing without global capture were considered critical. 18, 19 Radiofrequency energy was delivered at these sites (see below). For hemodynamically unstable VTs, substrate modification was performed, with cluster/linear lesions targeting sites identified by pace mapping, as well as abnormal electrograms. 15 The putative VT site of origin was defined using pace mapping to reproduce the VT QRS complex and to identify sites with a long stimulus to QRS interval. Limited activation and entrainment information were used to corroborate the pace map information when possible. Typically, lesions were delivered through the sites of best pace map with long stimulus to QRS (>30 ms). The ablation lesions were extended to target markedly abnormal fractionated split and late potentials and, for endocardial ablation, were typically anchored to the valve annuli ( Figure 1 ). Specific emphasis was given to target abnormal potentials recorded within a 2-to 3-cm radius of the region of interest, defined by entrainment mapping or pace mapping techniques, with the end point of signal modification or elimination ( Figure 2 ). Epicardial radiofrequency lesions always avoided large coronary vessels by at least 1 cm based on cine angiography. If inducibility of monomorphic VT persisted after ablation, residual inducible VTs were remapped and targeted using the techniques described earlier.
Radiofrequency energy application with the 4-mm standard catheter was set at 50 W and 55°. Open-irrigated ablation targeted a maximum temperature of 42° and a maximum impedance drop of 12 to 15 Ohms with power 20 to 50 W. Closed-irrigated ablation was set to deliver 20 to 50 W, targeting a maximum temperature of 45° and maximum impedance drop of 12 to 15 Ohms. Lesion duration was typically set for 60 to 90 seconds but was further increased to ≥3 minutes in duration at sites associated with transient suppression of VT with monitoring to confirm stable impedance drop, particularly at sites suspected of harboring intramural substrate. The amount of fluid in the epicardial space associated with the open irrigated catheter was monitored with intracardiac echocardiography and continuous arterial blood pressure monitoring for evidence of hypotension and drained intermittently or continuously to preclude hemodynamic compromise. At the end of the ablation procedure, 2 to 3 mg/kg of triamcinolone was routinely administered intrapericardially to reduce inflammation.
Outcomes
Long-term outcomes included (1) survival free of any VT (defined as any sustained VT on ICD interrogation or 12-lead ECG) after single or multiple procedures, (2) reduction of VT burden, and (3) survival free of cardiac transplantation. The acute procedural outcomes consisted of noninducibility of any VT (excluding very fast [<250 ms] nonclinical VTs/ventricular flutter). The acute efficacy was assessed on the basis of inducibility of VT at the end of the ablation procedure with a consistent stimulation protocol (up to triple extrastimuli from ≤2 ventricular sites with at least 2 drive CLs) and at the time of repeat programmed stimulation before hospital discharge noninvasively from a single RV site via the ICD system (noninvasive programmed stimulation or noninvasive programmed stimulation [NIPS]).
Clinical Follow-Up
Patients were evaluated at 4 to 8 weeks after ablation and then at 3-to 6-month intervals. For patients not followed at our institution, the referring cardiologists were contacted and ICD interrogations reviewed to determine VT recurrence. Telephone interviews were performed at 6-and 12-month intervals with patients or family members to confirm the absence of arrhythmias symptoms. The Social Security Death Index database was queried for vital status. (13) Hyperlipidemia, n (%) 65 (23) Chronic kidney disease, n (%) 57 (20) Chronic obstructive pulmonary disease, n (%) 26 (9) Obstructive sleep apnea, n (%) 24 (8) Previous cardiac arrest, n (%) 26 (9) History of unexplained syncope, n (%) 64 (22) History of atrial fibrillation, n (%) 66 (23) NYHA class III/IV, n (%) 84 (30) ICD, n (%) 240 (85) Clinical presentation with VT storm, n (%) 71 ( Amiodarone before procedure, n (%) 166 (59) Intravenous amiodarone before procedure, n (%) 29 (10) Daily dose of amiodarone before the procedure, mg 290±148
Statistical Analysis
Continuous variables are reported as mean±SD or median (quartiles) and categorical variables as counts and %. ICD indicates implantable cardioverterdefibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; and VT, ventricular tachycardia.
among the same patients were compared using paired-sample parametric (paired t test) or nonparametric (paired Wilcoxon signed-rank test) tests. Categorical variables were compared using chi-square test or Fisher exact test when appropriate. Survival curves were generated by the Kaplan-Meier method and compared with the log-rank test. Univariable and multivariable Cox proportional hazards analysis (using the forward stepwise model selection procedure) was used to test the association between the outcome event and baseline covariates. VT recurrence over follow-up was included as a time-dependent covariate. Only variables with P value <0.1 at univariable analysis were entered as covariates in the multivariable model. Two-tailed tests were considered statistically significant at the 0.05 level. Analyses were performed using IBM SPSS version 23.0 software (SPSS Inc, Chicago, IL).
Results

Study Population
Baseline characteristics of the study population are summarized in Table 1 . Two-hundred and eighty-two consecutive patients with NIDCM (age 59±15 years, 80% males) underwent CA after failure of 2 (1-2) AADs. Forty-five (16%) patients were referred after a previous endocardial CA attempt at an outside Institution. At baseline, 166 (59%) patients were receiving amiodarone therapy (intravenous infusion only in 29 cases). The mean preprocedure daily oral amiodarone dose was 290±148 mg. In 37 (13%) patients, sotalol or at least one class I AAD had been attempted before ablation (Figure 3 ). In 71 (25%) patients, the clinical presentation was VT storm, defined as ≥3 appropriate ICD interventions in 24 hours or incessant VT.
CA and Acute Procedural Outcomes
Ablation characteristics are summarized in Table 2 . A total of 442 procedures were performed among the 282 patients (median 1; range 1-8 procedures per patient). A second procedure was performed in 66 (23%) patients and 3 or more procedures in 36 (13%). Among the 102 (36%) patients with multiple procedures, the indication for repeat procedure was VT recurrence in 68/102 (67%) patients and persistent VT inducibility at postprocedure programmed ventricular stimulation or NIPS in the remaining 34/102 (33%) patients. A total of 172/442 (38%) procedures were performed under general anesthesia. In 21 (5%) procedures, mechanical hemodynamic support was used because of periprocedural hemodynamic instability (mostly after year 2010). The majority of the procedures were performed via a retrograde transaortic approach; an antegrade transseptal approach was used in 31 (7%) cases.
During the procedure, a median number of 2 (1-4) different VTs were induced with a mean CL of 386±98 ms. At least one hemodynamically unstable VT was induced in 239 (85%) patients. All patients underwent endocardial mapping and ablation. The interventricular septum was identified as a source of VT and targeted for ablation in 84 (30%) patients. In 28 (10%) cases, the coronary cusp region was targeted for ablation. Epicardial mapping was performed in 168 (38%) procedures (122 patients) and epicardial ablation in 118 (27%) procedures (90 patients).
At the end of the last procedure, a total of 262 (92%) patients underwent programmed ventricular stimulation; in 20 cases, this was not performed because of unstable patient conditions. The clinical VT was still inducible in 32 (12%) patients, and 46 (18%) patients had at least one nonclinical VT still inducible. A total of 101 (36%) patients underwent NIPS from the ICD a median of 3 (2-4) days after the last procedure: the clinical VT was not inducible in 84/101 (83%) patients while noninducibility of any VT was achieved in 63/101 (62%) patients.
Procedural Complications
A total of 19 (4%) complications occurred during the 442 procedures ( Table 2) . Two patients had pericardial tamponade requiring open-chest surgery to control the bleeding. In both cases, the event occurred during pericardial access: in one because of a perforation of the middle cardiac vein and in the other one because of laceration of the RV free wall. These 2 patients had concomitant epicardial cryo-ablation targeting the perivalvular epicardium guided by endocardial unipolar 
Long-Term Outcomes
Events occurring during the follow-up period are summarized in Table 3 . After a median follow-up of 48 (19-67) months, 24 patients underwent heart transplantation and 43 died. Overall transplant-free survival was 76% and 68% at 60-and 120month follow-up, respectively (Figure 4) . Cumulative VT-free survival after the last procedure was 69% at 60-month followup ( Figure 5 ). Among the 58 patients with VT recurrences, a significant reduction of VT burden was observed, with 31/58 (53%) patients having only isolated (≤3 VT) episodes occurring during an average of 12 months after the procedure ( Figure 5 ).
At the last follow-up, 128 (45%) patients were only on β-blockers or no treatment, 41 (15%) were on sotalol or class I AADs, and 62 (22%) were on amiodarone ( Figure 3 ). The daily dose of amiodarone at last follow-up was 247±103 mg. Table 4 shows the results of the univariable and multivariable Cox proportional hazards analysis of correlates of events during follow-up. In multivariable analysis, LVEF≤35% (hazard ratio [HR] 2.60, 95% confidence interval [CI] 1.06-6.38; P=0.04) and inducibility of any VT with CL>250 ms at postprocedural NIPS (HR 3.53, 95% CI 1.42-8.80; P=0.007) were the only variables independently associated with VT recurrence during follow-up.
Recurrent VT over follow-up was independently associated with subsequent mortality or transplant in multivariable analysis (HR 12.12, 95% CI 4.58-32.05; P<0.001), as was New York Heart Association (NYHA) functional class III/IV (HR 2.97, 95% CI 1.10-7.98; P=0.031) and LVEF≤35% (HR 4.70, 95% CI 1.33-16.55; P=0.016).
Kaplan-Meier survival curves for transplant and VT recurrence are presented in Figures 4 and 5 .
Discussion
The present study reports the long-term results of CA of drugrefractory VT in the largest series of patients with NIDCM to date. The major findings are as follows: (1) CA of VT in patients with NIDCM is a safe and effective approach to achieve long-term arrhythmia control in most patients; (2) VT recurrence after the last procedure, n (%) 58 (21) Death, n (%) 43 (15) Heart transplant, n (%) 24 (9) Amiodarone at last follow-up, n (%) 62 (22) Amiodarone dose at last follow-up, mg 248±103 Sotalol or class I arrhythmic drugs at last follow-up, n (%) 41 (15) Continuous variables are reported as mean±SD or median (quartiles) and categorical variables as counts and %. VT indicates ventricular tachycardia.
severely depressed LVEF (≤35%) and persistent inducibility of any VT at postprocedure NIPS were the only clinical factors independently related to VT recurrence after ablation; (3) VT recurrence over follow-up was strongly associated with an increased risk of subsequent death or transplant.
The management of recurrent VT in the setting of NIDCM is challenging, and evidence supporting the benefit of CA mainly stems from small retrospective studies, with discordant outcomes and arrhythmia-free survivals ranging from 30% to 71%. 1, 4, [7] [8] [9] [10] [11] 15, [20] [21] [22] Our findings confirm and extend the results of the prior studies and show that endocardial with adjuvant epicardial mapping and ablation when indicated (ie, early recurrence of VT or persistent inducibility after endocardial-only ablation) provides good long-term outcomes, with 69% of patients having no VT at 60-months follow-up and infrequent or isolated recurrent episodes in most of the remaining patients ( Figure 5 ). Moreover, arrhythmia control was achieved without requiring long-term AAD therapy with amiodarone in the majority of patients ( Figure 3) . The possibility to discontinue amiodarone after CA seems particularly attractive, considering that 75 (27%) patients in our series were <50 years old and given the risk of toxicity related to long-term exposure to this drug. 23 In addition, in a recent pooled analysis of randomized controlled trials comparing CA versus AADs, we have shown that treatment with amiodarone was associated with increased risk of mortality. 24 Although the acute procedural end points evolved during the 15-year period of the study, the ablation approaches were uniform and always started with endocardial-only procedures, reserving adjuvant epicardial mapping and ablation in patients with VT recurrence or persistent VT inducibility after endocardial-only ablation. Of note, all of the major complications observed in our study occurred during pericardial access or epicardial mapping/ablation ( Table 2 ). This finding is in line with prior reports on endocardial-epicardial ablation and further highlights the concept that pericardial access is definitively associated with increased risks, albeit small, supporting the notion that epicardial mapping/ablation should be reserved for select cases and not as a first-line approach in every patient with NIDCM. 25 The occurrence of pericardial adhesions preventing future pericardial accesses, even if reduced by the administration of intrapericardial steroids, should also be taken into account. These considerations justify the need for a comprehensive substrate ablation whenever pericardial access is obtained to minimize the need for repeated epicardial procedures.
As previously reported by our group and others, the arrhythmic substrate in patients with NIDCM frequently involves the basal interventricular septum. 2, 22, 26 In our series, the interventricular septum was identified as a source of VT and targeted for ablation in 84 (30%) patients, and in additional 28 (10%) cases, the coronary cusp region was also targeted. Our data confirm the importance of the interventricular septum and LV ostium region as a common site of origin of VT in patients with nonischemic cardiomyopathy.
In line with previous reports, we found that severely depressed LVEF and persistent VT inducibility at postprocedure NIPS were the only independent predictors of VT recurrence at follow-up, confirming postprocedure NIPS as an important prognostic tool to identify patients with not only ischemic cardiomyopathy but also NIDCM who may need additional ablation. 6, 7, 27 In contrast, we found that programmed stimulation at the end of the procedure was not associated with increased risk of VT recurrence over follow-up. The predictive role of programmed stimulation at the end of the ablation procedure in patient with NIDCM has been investigated in few prior studies with conflicting results. 6, 7, 28 Several previous reports failed to demonstrate predictive value of noninducibility at the end of the procedure for VT recurrence, which is consistent with our results. 28 The lack of predictive value of postprocedure programmed ventricular stimulation despite the strong association between inducibility at NIPS and arrhythmia-free survival may be explained by the imperfect reproducibility and probabilistic nature of VT induction with programmed stimulation, residual effect of AAD medications at the end of the procedure, alterations in the autonomic tone, and procedural sedation/anesthesia.
The overall transplant-free survival in our study population was of 68% at 120 months. Freedom from recurrent VT after CA was independently associated with a significant reduction in all-cause mortality/transplant. This observation confirms and expands prior single-center observational studies, [29] [30] [31] as well as the results of a recent multicenter VT ablation registry. 20 In addition, advanced NYHA class and severely depressed LVEF were associated with higher risk of transplant in multivariable analysis. Although the latter 2 factors cannot be modified significantly by therapeutic interventions, the finding of an independent association between VT recurrence and subsequent mortality regardless of underlying comorbidities and severity of heart failure status is of particular interest and would suggest that a more aggressive treatment with early consideration of repeat ablation procedures to eliminate recurrent VT may translate into a mortality benefit.
Study Limitations
This was a single-center observational study summarizing a 15-year experience with CA in patients with NIDCM. The outcomes we reported reflect the experience of our tertiary referral center and may not be generalized to lower volume Institutions with less experience with endocardial and epicardial VT CA. The choice for the specific ablation approach (ie, endocardialonly versus endocardial-epicardial ablation) and the additional therapeutic strategies implemented during follow-up (including repeat CA and continuation/discontinuation of AADs, such as amiodarone) was not randomized, and as expected, the acute ablation end points evolved over the multiyear study period. However, given the single center nature of the study, the ablation approaches and protocols adopted were uniform. In this regard, the decision to perform endocardial-epicardial mapping and ablation was driven by 4 criteria, namely, (1) the 12-lead ECG of the VT suggested an epicardial origin; (2) evidence of epicardial substrate on imaging studies (eg, magnetic resonance, intracardiac echocardiography); (3) endocardial unipolar electrogram abnormality (<8.3 mV) in the presence of no or minimal bipolar (<1.5 mV) electrogram abnormality; and (4) failure of endocardial ablation (VT recurrence or persistent inducibility of VT after endocardial ablation). Patients, who underwent endocardial-only ablation, were enrolled earlier in the experience and, as a result, also had a longer follow-up, which may potentially act as a bias. Furthermore, the year of enrollment may also have influenced the decision to perform epicardial ablation because our threshold for proceeding with an epicardial ablation became lower starting in year 2004 (only 20% of the epicardial ablations were performed before 2004 in our series). Given the observational nature of the study, we could not fully assess the impact of evolving mapping technologies, including the adoption of unipolar voltage mapping and multielectrode high-density mapping on the outcomes. However, we did not find a significant interaction between year of enrollment and procedural outcomes (Data Supplement). Finally, our survival analysis shown in Figure 5 is referenced to the date of the last procedure, which can only be determined retrospectively. However, because good arrhythmia control frequently requires more than a single procedure in patients with nonischemic cardiomyopathy and VT, it was appropriate to establish a reference point regarding outcome that recognized this frequent requirement.
Conclusions
Endocardial with adjuvant epicardial ablation of VT in NIDCM provides good long-term arrhythmia-free survival.
The majority of patients have complete VT control, and most of the remaining patients have a substantial improvement in VT burden with limited need for AADs. However, given the significant burden of associated comorbidities and severity of heart failure, up to one third of patients died or required heart transplant over follow-up. Recurrent VT was found to be independently associated with increased risk of subsequent death/transplant. Further studies are necessary to evaluate whether a more aggressive treatment of recurrent VT may translate into a mortality benefit in these patients.
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